CBR-5884 #24471
Product Information
Product Usage Information
Storage
Product Description
| Molecular Weight | 336.4 g/mol |
| Purity | >98% |
| Molecular Formula | C14H12N2O4S2 |
| CAS | 681159-27-3 |
| Solubility | Soluble in DMSO at 50 mg/mL or DMF at 50 mg/mL. |
Background
CBR-5884 is a small-molecule inhibitor of phosphoglycerate dehydrogenase (PHGDH), which catalyzes the first step in the serine biosynthesis pathway. An increase in serine biosynthesis supports growth and proliferation of cancer cells, which is seen by amplification and overexpression of PHGDH in some melanoma and breast cancers (1). CBR-5884 inhibited the proliferation of melanoma and breast cancers that displayed increased levels of serine synthesis, but had no effect on cells that rely on extracellular serine uptake. CBR-5884 disrupted PHGDH oligomerization and decreased serine biosynthesis by 30% in cancer cells (2). CBR-5884 treatment of teratocarcinoma cells significantly decreased the growth rate in a dose-dependent manner (3). Inhibition of PHGDH and serine biosynthesis caused accumulation of reactive oxygen species, DNA damage, and apoptosis in leukemic cells (4). Treating human myeloma cells with CBR-5884 reduced proliferation, while inhibition of PHGDH by CBR-5884 reduced proliferation and sensitized glioblastoma cells to hypoxia-induced cell death (5,6).
- Locasale, J.W. (2013) Nat Rev Cancer 13, 572-83.
- Mullarky, E. et al. (2016) Proc Natl Acad Sci U S A 113, 1778-83.
- Sharif, T. et al. (2018) Cell Death Dis 9, 990.
- Garcia-Cuellar, M.P. et al. (2020) Blood Adv 4, 3626-3638.
- Elsaadi, S. et al. (2021) Exp Hematol Oncol 10, 3.
- Engel, A.L. et al. (2020) Br J Cancer 122, 1391-1398.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.